Aura Biosciences
AURA
72 hedge funds and large institutions have $328M invested in Aura Biosciences in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 11 reducing their positions, and 7 closing their positions.
374% more call options, than puts
Call options by funds: $90K | Put options by funds: $19K
227% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 11
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
29% more capital invested
Capital invested by funds: $254M → $328M (+$73.4M)
13% more funds holding
Funds holding: 64 → 72 (+8)
3.25% more ownership
Funds ownership: 71.95% → 75.2% (+3.2%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$23.5M |
| 2 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$13.2M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$11.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$9.72M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$6.48M |
| 2 |
Citigroup
New York
|
-$867K |
| 3 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
-$221K |
| 4 |
WIC
Water Island Capital
New York
|
-$203K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$161K |
AURA Hedge Fund Activity: Q4 2023 in Review
72 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q4 2023, worth a combined $328M — up 29% from $254M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new AURA positions and 7 closed out — a net gain of 9 holders — while 36 added to existing stakes and 11 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $23.5M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $6.48M sold.
- 72 institutional investors held Aura Biosciences (AURA) as of Q4 2023, up from 64 in Q3 2023.
- Funds reported $328M of Aura Biosciences stock for Q4 2023, up 29% quarter-over-quarter.
- 16 funds opened new Aura Biosciences positions in Q4 2023 and 7 closed out, a net change of +9 holders.
- The largest Aura Biosciences buyer in Q4 2023 was Eventide Asset Management, an estimated $23.5M added.
- The largest Aura Biosciences seller in Q4 2023 was Rock Springs Capital Management, an estimated $6.48M sold.
Based on aggregated 13F filings for Q4 2023.